

1 Gary L. Wilson (CA Bar # 139358)  
GWilson@robinskaplan.com  
2 Munir R. Meghjee (MN Bar # 301437)  
MMeghjee@robinskaplan.com  
3 Megan J. McKenzie (MN Bar # 388081)  
MMcKenzie@robinskaplan.com  
4 ROBINS KAPLAN LLP  
800 LaSalle Avenue  
5 Suite 2800  
Minneapolis, MN 55402-2015  
6 Telephone: 612-349-8500  
Facsimile: 612-339-4181

7 *Attorneys for Plaintiffs*

8 UNITED STATES DISTRICT COURT  
9 EASTERN DISTRICT OF CALIFORNIA

10  
11  
12 Athlean Harper-Mosley,  
13 Plaintiff,  
14 v.  
15 Bristol-Myers Squibb Company,  
Otsuka Pharmaceutical Co., Ltd., and  
16 Otsuka America Pharmaceutical, Inc.,  
17 Defendants.

Civil Action No.: \_\_\_\_\_

**COMPLAINT AND DEMAND FOR  
JURY TRIAL**

18  
19 Plaintiff, Athlean Harper-Mosley ("Plaintiff"), by and through Plaintiff's  
20 undersigned counsel, brings this civil action against Defendants above-named, and  
21 alleges as follows:

22 **INTRODUCTION**

23 1. This is an action for damages suffered by Plaintiff as a direct and proximate  
24 result of Defendants' wrongful conduct in connection with the development, design,  
25 testing, labeling, packaging, promoting, advertising, marketing, distribution, and selling  
26 of Defendants' prescription drug Abilify.

27 2. Defendants manufacture, promote, and sell Abilify as a prescription drug that  
28

1 treats depression, bipolar I disorder, and schizophrenia. Abilify is manufactured as  
2 tablets, oral solution, and injection.

3 3. Defendants' drug Abilify harmed Plaintiff, having caused harmful compulsive  
4 behaviors including compulsive gambling, resulting in substantial financial, mental, and  
5 physical damages.

6 4. Defendants knew or should have known that Abilify, when taken as  
7 prescribed and intended, causes and contributes to an increased risk of serious and  
8 dangerous side effects including, without limitation, uncontrollable compulsive  
9 behaviors such as compulsive gambling.

10 5. Defendants' labeling in Europe and Canada warns about the risk of  
11 "pathological gambling."

12 6. Defendants did not warn, advise, educate, or otherwise inform Abilify users  
13 or prescribers in the United States about the risk of compulsive gambling or other  
14 compulsive behaviors. Prior to January 2016, the US label made no mention of  
15 pathological gambling or compulsive behaviors whatsoever. In January 2016,  
16 Defendants simply added "pathological gambling" to the postmarketing experience  
17 section of the US label in January 2016. Defendants do not, however, make any mention  
18 of gambling in the patient medication guide, the source of information most likely  
19 viewed by physicians and patients. The US label also still makes no mention of other  
20 compulsive behaviors, and does not contain an adequate warning about the risk of  
21 compulsive gambling or caution that patients should be monitored carefully.

22 **PARTIES**

23 7. Plaintiff is an adult resident and citizen of Sacramento, California.

24 8. Plaintiff was prescribed and took the prescription drug Abilify and as a result  
25 developed compulsive gambling behaviors. Plaintiff began taking Abilify in or around  
26 July 2007, began compulsively gambling shortly thereafter, and stopped compulsively  
27 gambling soon after Plaintiff had ceased taking Abilify in or around May 2014. Due to  
28 Defendants' conduct, as detailed herein, Plaintiff's injuries and their relationship to

1 Abilify were not discovered until 2014.

2 9. By way of example, as a result of Abilify use, Plaintiff has suffered the  
3 following losses: monetary losses in excess of \$65,000, loss of financial stability, and  
4 other mental, physical, and economic losses. The injurious impact of Abilify on  
5 Plaintiff's brain constitutes a physical injury.

6 10. As a result of Abilify use, Plaintiff has suffered, and will continue to suffer,  
7 neuropsychiatric and physical injury, emotional distress, harm, and economic loss as  
8 alleged herein.

9 11. Defendant Bristol-Myers Squibb Company ("Bristol-Myers") is incorporated  
10 in Delaware, with its principal executive office at 345 Park Avenue, New York, New  
11 York. Upon information and belief, Bristol-Myers owns and operates six facilities in the  
12 state of New Jersey.

13 12. Defendant Otsuka Pharmaceutical Co., Ltd. is a foreign Japanese company,  
14 with its principal office at 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo 101-8535,  
15 Japan and has a registered agent located at 351 West Camden Street, Baltimore,  
16 Maryland per records filed with the Maryland Department of Assessments and Taxation  
17 Business Services. Abilify is a trademark of Defendant Otsuka Pharmaceutical Co., Ltd.  
18 Defendant Otsuka Pharmaceutical Co. Ltd. wholly owns Otsuka America, Inc. ("OAI"),  
19 a holding company established in the United States in or around 1989. OAI is the parent  
20 of Defendant Otsuka America Pharmaceutical, Inc. ("OAPI"), Otsuka Pharmaceutical  
21 Development & Commercialization, Inc. ("OPDC"), and Otsuka Maryland Medicinal  
22 Laboratories, Inc. ("OMML").

23 13. Defendant OAPI is incorporated in Delaware, with its principal place of  
24 business at 508 Carnegie Center Princeton, New Jersey. OAPI oversees all  
25 pharmaceutical commercial activities in North America. OAPI developed, distributed,  
26 and marketed Abilify with OPC.

27 14. At all times relevant to this Complaint, Defendant Otsuka Pharmaceutical Co.  
28 Ltd., OAI, OAPI, OPDC, and OMML (the "Otsuka entities") have operated in concert as

1 it relates to the development, research, distribution, manufacturing, and/or marketing  
2 of Abilify. OPC has control over its subsidiaries daily affairs and operations with  
3 respect to Abilify. The Otsuka entities work in concert as a single operation known as  
4 the Otsuka Group.

5 15. Defendant Bristol-Myers has operated in concert with the other Defendants  
6 and jointly marketed, sold, and promoted Abilify in the United States with the Otsuka  
7 Group, through Defendant OAPI and otherwise.

8 16. Defendants are collectively engaged in the development, design, testing,  
9 labeling, packaging, promoting, advertising, marketing, distribution, and selling of  
10 pharmaceutical products, including Abilify. Otsuka “discovered” Abilify in 1988,  
11 obtained approval in the United States in November 2002 and in Japan in January 2006.

12 17. Defendants Bristol-Myers and Otsuka are and have been engaged in the  
13 business of researching, testing, developing, manufacturing, packaging, distributing,  
14 licensing, labeling, promoting, marketing and selling, either directly or indirectly  
15 through third parties or related entities, the pharmaceutical drug Abilify, in all states  
16 and throughout the United States.

17 **JURISDICTION**

18 18. This Court has federal subject matter jurisdiction pursuant to 28 U.S.C. § 1332  
19 because Plaintiff and Defendants are citizens of different States and the amount in  
20 controversy exceeds \$75,000 exclusive of interest and costs.

21 19. Venue is proper in this judicial district pursuant to 28 U.S.C. § 1391.

22 20. In particular, a foreign defendant may be sued in this judicial district pursuant  
23 to 28 U.S.C. § 1391(c)(3).

24 21. The domestic Defendant entities are residents of, and operate in, this judicial  
25 district for purposes of venue pursuant to 28 U.S.C. §§ 1391(b)(1), (c)(2), (d).

26 22. At all times relevant to this action, the Defendants have been engaged either  
27 directly or indirectly in the business of marketing, promoting, distributing, and selling  
28 prescription drug products, including the Abilify products, within the State of

1 California, with a reasonable expectation that the products would be used or consumed  
2 in this state, and thus regularly solicited or transacted business in this state.

3 23. This Court has personal jurisdiction over Otsuka Pharmaceutical Co., Ltd.  
4 based on its contacts with California relating to the subject matter of this action and  
5 because Otsuka Pharmaceutical Co., Ltd. has continuous and systematic contacts with  
6 this judicial district. On information and belief, Otsuka Pharmaceutical Co., Ltd.  
7 regularly places goods into the stream of commerce for distribution in California and  
8 throughout the United States. Members of Otsuka Pharmaceutical Co., Ltd.  
9 continuously communicate from Japan with members of Otsuka America  
10 Pharmaceutical, Inc.

11 24. Defendants are subject to the *in personam* jurisdiction of this Court, and venue  
12 is therefore proper herein pursuant to 28 U.S.C. § 1391, because Defendants did and do  
13 business within and have continuous and systematic contacts with the State of  
14 California, have consented to jurisdiction in the State of California and/or committed a  
15 tort in whole or in part in the State of California against Plaintiff, as more fully set forth  
16 herein. On information and belief, Defendants also advertised in this district, made  
17 material omissions and representations in this district, and breached warranties in this  
18 district.

19 25. Jurisdiction is proper under Cal. Code Civ. Pro. § 410.10 and the due process  
20 clause of the Constitution because Defendants have sufficient minimum contacts with  
21 the State of California related to Abilify and have purposefully directed conduct toward  
22 the State of California.

23 **FACTUAL BACKGROUND**

24 26. Abilify was first introduced to the market in the United States in or around the  
25 fall of 2002. Abilify is an atypical anti-psychotic prescription medicine discovered by  
26 Defendant Otsuka Pharmaceutical Co., Ltd.

27 27. In or around October or November of 2012, the European Medicines Agency  
28 required that Defendants warn patients and the medical community in Europe that

1 Abilify use included the risk of pathological gambling.

2 28. In particular, the European Medicines Agency required the European labeling  
3 for Abilify to carry the following language in the Special Warnings and Precautions For  
4 Use section of the label:

5 **Pathological gambling**

6 **Post-marketing reports of pathological gambling have been**  
7 **reported among patients prescribed ABILIFY, regardless of**  
8 **whether these patients had a prior history of gambling. Patients**  
**with a prior history of pathological gambling may be at increased**  
**risk and should be monitored carefully.**

9 29. The European labeling for Abilify also carries additional language concerning  
10 adverse reactions that have been reported during post-marketing surveillance relating to  
11 gambling side effects. Under a section entitled “Undesirable effects,” it provides:

12 **Psychiatric disorders: agitation, nervousness, pathological**  
13 **gambling, suicide attempt, suicidal**  
**ideation, and completed suicide.**

14 30. In or around November 2015 Canadian regulators concluded that there is “a  
15 link between the use of aripiprazole and a possible risk of pathological gambling or  
16 hypersexuality” and found an increased risk of pathological (uncontrollable) gambling  
17 and hypersexuality with the use of Abilify.

18 31. In or about November 2015 the following warning statement for the risk of  
19 pathological gambling was added to the Canadian prescribing information for Abilify:

20 **Pathological Gambling**

21 **Post-marketing reports of pathological gambling have been**  
22 **reported in patients treated with ABILIFY. In relation to**  
23 **pathological gambling, patients with a prior history of gambling**  
**disorder may be at increased risk and should be monitored**  
**carefully.**

24 32. Despite these warnings and advisories in Europe and Canada – for the same  
25 drug sold to patients in the United States – the labeling for Abilify in the United States  
26 does not adequately warn about the risk of compulsive gambling and contained no  
27 mention that pathological gambling has been reported in patients prescribed Abilify  
28 until January 2016 when pathological gambling was added only to the Postmarketing

1 Experience section of the label. Defendants do not make any mention of gambling in the  
2 patient medication guide, a source of information likely viewed by physicians and  
3 patients.

4 33. The labeling for Abilify in the United States contained no mention of the word  
5 “gambling” until January 2016.

6 34. Defendants wrongfully and unjustly profited at the expense of patient safety  
7 and full disclosure to the medical community by failing to include language about  
8 gambling in the United States labeling and by failing to otherwise warn the public and  
9 the medical community about Abilify’s association with gambling – despite  
10 opportunities and a duty to do so. As a result, Defendants have made significantly more  
11 revenue from Abilify sales in the United States compared to Europe.

12 35. Defendant Bristol-Myers touts Abilify as its “2013 largest-selling product”  
13 noting sales of \$2.3 billion. Defendant Bristol-Myers recently reported U.S. revenues  
14 from Abilify sales of \$417 million over three months ending June 30, 2014, and  
15 worldwide revenues of \$555 million over the same time period.

16 36. Since its introduction to the United States market, Abilify has generally been  
17 used to treat patients with schizophrenia, bipolar disorder, as an adjunct for depression,  
18 and autism spectrum disorders.

19 37. In 2001, Defendant Otsuka Pharmaceutical Co., Ltd. submitted a New Drug  
20 Application (“NDA”) to the United States Food and Drug Administration (“FDA”) for  
21 Abilify (aripiprazole). This initial NDA sought approval to market Abilify in 2, 5, 10, 15,  
22 20 and 30 mg tablets as a treatment for schizophrenia. The NDA was approved on  
23 November, 15 2002.

24 38. In November 2002, the FDA required Defendants to submit results of Study  
25 138047 to address the longer-term efficacy of Abilify in the treatment of adults with  
26 schizophrenia.

27 39. On December 3, 2002, Defendant Otsuka America Pharmaceutical, Inc.,  
28 submitted a Supplemental New Drug Application (NDA 21-436/S-001) on the longer-



1 term efficacy of Abilify in the treatment of schizophrenia. This application was  
2 approved on August 28, 2003.

3 40. In June 2003, Otsuka Maryland Research Institute submitted another  
4 Supplemental New Drug Application (NDA 21-436/S-002) for Abilify tablets as a  
5 treatment for bipolar disorder. This application was approved on September 29, 2004.

6 41. In May 2007, Otsuka Pharmaceutical Development & Commercialization, Inc.,  
7 submitted another Supplemental New Drug Application (NDA 21-436/S-018) for Abilify  
8 tablets as an adjunctive treatment for patients with major depressive disorder. This  
9 application was approved on November 16, 2007.

10 42. In contrast, in Europe, Abilify is not indicated to treat depression. The  
11 European Medicines Agency declined to approve Abilify as an add-on treatment for  
12 depression because of concerns about its efficacy for that indication.

13 43. In or around 1999, Defendants Bristol-Myers and Otsuka entered into an  
14 agreement to co-develop and “commercialize” Abilify (hereinafter referred to as  
15 “Defendants’ Marketing Agreement”). Under terms of Defendants’ Marketing  
16 Agreement, Defendant Bristol-Myers was to market and promote Abilify in the United  
17 States and the European Union, in collaboration with Defendant Otsuka Pharmaceutical  
18 Co., Ltd., and under Defendant Otsuka Pharmaceutical Co., Ltd.’s trademark.

19 44. Defendants’ Marketing Agreement also provided that Defendants Bristol-  
20 Myers and Otsuka Pharmaceutical Co., Ltd. would collaborate to complete clinical  
21 studies for schizophrenia, and that Defendant Bristol-Myers would conduct additional  
22 studies for new dosage forms and new indications.

23 45. Defendant Bristol-Meyers began co-promoting Abilify with Defendant Otsuka  
24 Pharmaceutical Co., Ltd. in the United States and Puerto Rico in or around November  
25 2002. Defendants’ Marketing Agreement was extended in or around 2009.

26 46. Defendant Bristol-Myers’ relationship with Otsuka had been due to expire in  
27 or around April 2015, just after the predicted expiration of Abilify’s patent protection in  
28 the United States. According to a revised marketing agreement, Defendant Bristol-



1 Myers purported to no longer market and promote Abilify as of January 1, 2013, but  
2 would continue to carry out its other responsibilities, including manufacturing for sale  
3 to third-party customers. Nevertheless, Defendant Bristol-Myers continued to market  
4 and promote Abilify, for example, through its website, through September 2015.

5 47. Defendants had, or should have had, knowledge that Abilify can cause  
6 compulsive behaviors like gambling. Despite their significant collective resources, and  
7 signals that Abilify is associated with compulsive behaviors such as gambling,  
8 Defendants have failed to fully and adequately test or research Abilify and its  
9 association with compulsive behaviors to the detriment of Plaintiff, Abilify users, the  
10 public, the medical community, and prescribing doctors.

11 48. Compulsive gambling is a major psychiatric disorder. The American  
12 Psychiatric Association's *Diagnostic and Statistical Manual of Mental Disorders* (DSM) first  
13 recognized pathological gambling as a psychiatric disorder in 1980.

14 49. Originally, the disorder was classified as an impulse control disorder. The  
15 current version of the DSM, the DSM-V, renamed pathological gambling as "gambling  
16 disorder." DSM-V reclassified gambling disorder under the category Substance-Related  
17 and Addictive Disorders in order to reflect evidence that gambling behaviors activate or  
18 are activated by reward systems similar to those activated by drugs of abuse, and  
19 produce some behavioral symptoms comparable to those produced by substance abuse  
20 disorders.

21 50. Abilify is a partial and full dopamine agonist. Dopamine is a neurotransmitter  
22 that helps control the brain's reward and pleasure centers.

23 51. Dopamine's role in compulsive behavior and pathological gambling is well-  
24 known. Dopaminergic reward pathways have frequently been implicated in the  
25 etiology of addictive behavior. Scientific literature has identified dopamine as a  
26 potential cause of pathological gambling for years.

27 52. Abilify's dopaminergic activity at the mesolimbic circuit, especially at the  
28 nucleus accumbens, has been associated with compulsive behavior in Abilify patients.

1 53. Defendants' September 2011 6-Month Periodic Safety Update Report  
2 acknowledges a plausible mechanism for pathological gambling. The Report states that  
3 an article, Chau et al., *The Neural Circuitry of Reward and Its Relevance to Psychiatric*  
4 *Disorders*, "does suggest a possible mechanism by which drugs that act on dopamine  
5 neurons, like aripiprazole, might possibly have some effect on behavior related to  
6 reward."

7 54. Defendants' September 2011 6-Month Periodic Safety Update Report  
8 submitted to the European Medicines Agency acknowledged seven serious reports of  
9 pathological gambling, three in the medical literature and four spontaneous reports.  
10 The report also noted sixteen cases of pathological gambling in the BMS company safety  
11 database.

12 55. The Medical Assessment of the pathological gambling cases in Defendants'  
13 September 2011 6-Month Periodic Safety Update Report did not exclude Abilify as the  
14 cause of the compulsive gambling adverse events. Defendants concluded that "a causal  
15 role of aripiprazole could not be excluded" or that "aripiprazole was suggested by the  
16 temporal relationship."

17 56. The European Final Assessment Report of the September 2011 6-Month  
18 Periodic Safety Update Report concluded that with regard to compulsive gambling "in  
19 all of the reported cases we have a (+) temporal; (+) dechallenge and in one case a (+)  
20 rechallenge."

21 57. Numerous case reports have been published in the medical literature linking  
22 Abilify to compulsive behavior, including at least seventeen cases of compulsive  
23 gambling. Gaboriau et al. examined case reports of compulsive gambling and found  
24 that the probability that pathological gambling was actually due to Abilify was  
25 "possible" in sixteen of the cases and "doubtful" in only one of the cases.

26 58. Several case reports demonstrate what is known as a challenge, de-challenge,  
27 and re-challenge.

28 59. Challenge is the administration of a suspect product by any route.

1       60. De-challenge is the withdrawal of the suspected product from the patient's  
2 therapeutic regime. A positive de-challenge is the partial or complete disappearance of  
3 an adverse experience after withdrawal of the suspect product. For example, a positive  
4 de-challenge occurs when a patient ceases use of Abilify and pathological gambling  
5 behaviors cease.

6       61. Re-challenge is defined as a reintroduction of a product suspected of having  
7 caused an adverse experience following a positive de-challenge. A positive re-challenge  
8 occurs when similar signs and symptoms reoccur upon reintroduction of the suspect  
9 product. For example, a positive re-challenge occurs when a patient reintroduces  
10 Abilify into her treatment regime and pathological gambling behavior reoccurs in a  
11 similar manner as such behaviors had existed when the patient previously used Abilify.

12       62. A positive de-challenge is considered evidence that a drug caused a particular  
13 effect, as is a positive re-challenge.

14       63. From May 1, 2009 to May 1, 2011, the FDA received thousands of serious  
15 adverse event reports concerning Abilify (n=4599), including over two-thousand serious  
16 adverse drug experiences of which 193 involved children (0-16 years old).

17       64. Serious adverse events are drug experiences including the outcomes of death,  
18 life-threatening events, hospitalization, disability, congenital abnormality, and other  
19 harmful medical events.

20       65. From 2005 to 2013, an FDA report showed that Abilify accounted for at least  
21 fifty-four reports of compulsive or impulsive behavior problems, including thirty  
22 reports of compulsive gambling, twelve reports of impulsive behavior, nine reports of  
23 hypersexuality, and three reports of compulsive shopping.

24       66. A disproportionality study of the FDA Adverse Event Reporting System  
25 showed a proportional reporting ratio for compulsivity of 8.6 for Abilify. A ratio of  
26 more than three indicates a signal of an adverse event.

27       67. An analysis of the FDA Adverse Event Reporting System shows an escalating  
28 number of reports. Twenty-nine reports of gambling behavior were made to the FDA in

1 2014.

2 68. The 2014 FDA Adverse Event Reporting System data shows a proportional  
3 reporting ratio for compulsive gambling of 64.3 for Abilify. The same data demonstrates  
4 Abilify is unique in this regard and compulsive gambling is not a class-wide problem  
5 among anti-psychotic medications.

6 69. Defendants have not adequately studied Abilify. A review of all the  
7 randomized clinical trials comparing Abilify to other schizophrenia drugs concluded  
8 that the information on comparisons was of limited quality, incomplete, and problematic  
9 to apply clinically.

10 70. Despite evidence that Abilify causes compulsive behaviors like pathological  
11 gambling and calls from the medical community to conduct further research and warn  
12 patients about this possible effect of Abilify, Defendants have either failed to investigate  
13 or conduct any studies on the compulsive behavior side effects of Abilify or failed to  
14 make public the results of any studies or investigations that they might have done.

15 71. Abilify is not very efficacious. According to a rigorous study by the Cochrane  
16 Collaboration, there is limited evidence that Abilify leads to symptom reduction when  
17 added to antidepressants and side effects are more frequent under Abilify augmentation  
18 treatment.

19 72. The Drug Facts Box for Abilify for major depression includes a “summary” of  
20 the combined data from the two identical six week randomized trials that were the basis  
21 for FDA drug approval for this indication. The box shows that Abilify has only a  
22 modest benefit: on average, patients on Abilify improved by 3 points more (*on a scale of*  
23 *60*) than patients on placebo, and only an additional 11% of patients had a clinically  
24 important response as defined in the trial.

25 73. Despite the risks of serious adverse events, and the lack of adequate testing,  
26 Defendants aggressively promoted Abilify, including illegal promotion for off-label use.  
27 In 2007, Defendant Bristol-Myers reportedly paid \$515 million to settle federal and state  
28 investigations into off-label marketing of Abilify for pediatric use and to treat dementia-

1 related psychosis. Defendant Otsuka American Pharmaceutical, Inc., later paid more  
2 than \$4 million to resolve the allegations.

3 74. The FDA issued a letter dated April 17, 2015 finding Abilify promotional  
4 material “false or misleading because it makes misleading claims and presentations  
5 about the drug.” The FDA found the material “misleading because it implies that  
6 Abilify offers advantages over other currently approved treatments for bipolar disorder  
7 or MDD when this has not been demonstrated.” The FDA also found the cited  
8 references “not sufficient to support claims and presentations suggesting that Abilify has  
9 been demonstrated to modulate dopaminergic and serotonergic activity, or modulate  
10 neuronal activity in both hypoactive and hyperactive environments in humans.”

11 75. Upon information and belief, Defendants have invested millions of dollars in  
12 teams of pharmaceutical sales representatives who visit and contact members of the  
13 medical community, including prescribing doctors, purporting to “educate” them about  
14 Abilify. Upon information and belief, these pharmaceutical sales representatives have  
15 not notified patients, the medical community, or prescribers in the United States that  
16 Abilify use causes, is linked to, or might be associated with compulsive gambling,  
17 pathological gambling, or gambling addiction.

18 76. Defendants have invested millions of dollars in “Direct to Consumer”  
19 advertising. None of the advertising in the United States notifies patients, the medical  
20 community, or prescribers that Abilify use causes, is linked to, or might be associated  
21 with compulsive gambling, pathological gambling, or gambling addiction.

22 77. Defendants’ Direct to Consumer advertising minimizes risks while over-  
23 promoting the drug.

24 78. As a result of Defendants’ misleading promotional campaigns, Abilify  
25 occupies the top sales position for a prescription drug in the United States (but has only  
26 reached seventh place in the global ranking of drug sales).

27 79. Defendants have made payments to doctors to promote Abilify. From August  
28 2013 to December 2014, \$10.6 million in payments relating to Abilify were made to

1 21,155 physicians in the United States.

2 80. To date, Defendants have not adequately notified or warned patients, the  
3 medical community, or prescribers in the United States that Abilify use causes, is linked  
4 to, and is associated with compulsive gambling, pathological gambling, or gambling  
5 addiction.

6 81. Defendants have not sent out any “Dear Doctor” letters to inform the medical  
7 community of the risk or association of Abilify use and gambling.

8 82. Under the heading “What are the possible side effects of ABILIFY?,” the  
9 labeling for Abilify in the United States does not list gambling, pathological or  
10 otherwise. Nor does it mention compulsive behaviors.

11 83. Likewise, the labeling for Abilify in the United States lists serious side effects  
12 that have been reported with Abilify, but did not list gambling, pathological or  
13 otherwise in any form until January 2016 when it was only added to the postmarketing  
14 experience section of the label. The label still does not mention compulsive behaviors  
15 other than pathological gambling or adequately warn patients about the risk of  
16 compulsive gambling. Defendants also do not make any mention of gambling in the  
17 patient medication guide, the source of information most likely viewed by physicians  
18 and patients.

19 84. The labeling in the United States contradicts the labeling in Europe and  
20 Canada by not providing adequate warnings and not cautioning that patients should be  
21 closely monitored, and does not adequately inform patients and physicians that  
22 gambling and other compulsive behaviors have been associated with Abilify use.

23 85. Defendant Otsuka America Pharmaceutical, Inc., maintains a website  
24 promoting Abilify, [www.abilify.com](http://www.abilify.com). The website includes, among other information,  
25 “tips for taking Abilify,” links to “a 30-day free trial & savings on refills,” and  
26 “important safety information” for Abilify. Although it has sections about “important  
27 safety information,” nowhere on the website does it mention the word “gambling.”

28 86. Also, Defendant Otsuka America Pharmaceutical, Inc., operated another

1 website promoting Abilify, [www.addabilify.com](http://www.addabilify.com). Prior to 2015, this website included,  
2 among other information, “important safety information,” “tips for family and friends,”  
3 “treatment FAQs,” “side effects FAQs,” and “what your doctor needs to know”  
4 concerning Abilify. Nowhere on the website did it mention the word “gambling.”

5 87. Defendant Bristol-Myers promotes Abilify on its own website, [www.bms.com](http://www.bms.com)  
6 (“BMS website”), noting it was approved in November 2002 and is “jointly marketed in  
7 the U.S. by Bristol-Myers Squibb and Otsuka America Pharmaceutical.” The BMS  
8 website also includes a link to the [www.abilify.com](http://www.abilify.com) website. Nowhere on the BMS  
9 website does it mention the word “gambling.”

10 88. Likewise, Defendant Otsuka Pharmaceutical Co., Ltd. promotes Abilify on its  
11 own website, [www.otsuka.co.jp/en/](http://www.otsuka.co.jp/en/) (“Otsuka website”), noting it was “researched and  
12 developed by Otsuka Pharmaceutical” and “launched” in the United States in 2002.  
13 Nowhere on the Otsuka website does it mention the word “gambling.”

14 **EQUITABLE TOLLING OF APPLICABLE STATUTES OF LIMITATIONS**

15 89. Plaintiff asserts all applicable state statutory and common law rights and  
16 theories related to the tolling or extension of any applicable statute of limitations,  
17 including the discovery rule and/or fraudulent concealment.

18 90. The discovery rule should be applied to toll the running of the statute of  
19 limitations until the Plaintiff discovered or reasonably should have discovered Plaintiff’s  
20 injury and the causal connection between the injury and Defendants’ product.

21 91. Despite reasonable and diligent investigation by Plaintiff into the causal  
22 connection between Plaintiff’s injury and Abilify, the cause and nature of Plaintiff’s  
23 injuries and their relationship to Abilify was not discovered until 2014. Therefore, under  
24 the appropriate application of the discovery rule, Plaintiffs’ suit was filed well within the  
25 applicable statutory limitations period.

26 92. Defendants are estopped from asserting a statute of limitations defense  
27 because all Defendants fraudulently concealed from Plaintiff the truth, quality and  
28 nature of Plaintiff’s injuries and the connection between the injuries and Defendants’



1 tortious conduct. Defendants, through their affirmative misrepresentations and  
2 omissions, actively concealed from Plaintiff and Plaintiff's prescribing physicians the  
3 true risks associated with Abilify.

4 93. Defendants were under a duty to disclose the true character, quality and  
5 nature of the risks associated with use of Abilify as this was non-public information over  
6 which Defendants had and continue to have exclusive control and because Defendants  
7 knew that this information was not available to Plaintiff, Plaintiff's medical providers  
8 and/or to Plaintiff's health-care facilities. In addition, Defendants are estopped from  
9 relying on any statute of limitation because of their intentional concealment of these  
10 facts.

11 94. Plaintiff had no knowledge that Defendants were engaged in the wrongdoing  
12 alleged herein. Because of the fraudulent acts of concealment of wrongdoing by  
13 Defendants, Plaintiff could not have reasonably discovered the wrongdoing at any time  
14 prior.

15 **FIRST CAUSE OF ACTION**  
16 **Strict Liability - Design, Manufacturing and Warning**

17 95. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
18 fully set forth herein and further alleges as follows:

19 96. Defendants had a duty to provide adequate warnings and instructions for  
20 Abilify, to use reasonable care to design a product that is not unreasonably dangerous to  
21 users, and to adequately test its product.

22 97. The Abilify manufactured and/or supplied to Plaintiff by Defendants was  
23 defective in design or formulation in that, when it left the hands of the manufacturer  
24 and/or supplier, it was in an unreasonably dangerous and a defective condition for its  
25 intended use and it posed a risk of serious compulsive behaviors and harm to Plaintiff  
26 and other consumers which could have been reduced or avoided, *inter alia*, by the  
27 adoption of a feasible reasonable alternative design.

28 98. The Abilify manufactured and/or supplied to Plaintiff by Defendants was

1 defective in design or formulation in that, when it left the hands of the manufacturer  
2 and/or supplier, Abilify had not been adequately tested, was in an unreasonably  
3 dangerous and a defective condition, and it posed a risk of serious compulsive behaviors  
4 and harm to Plaintiff and other consumers.

5 99. Also, Abilify's limited and unproven effectiveness did not outweigh the risks  
6 posed by the drug.

7 100. The Abilify manufactured and/or supplied to Plaintiff by Defendants was  
8 defective due to inadequate warnings or instructions concerning the true risks of its use.

9 101. Defendants knew or should have known through testing, scientific  
10 knowledge, advances in the field or otherwise, that the product created a risk of serious  
11 compulsive behaviors and harm, and was unreasonably dangerous to Plaintiff and other  
12 consumers, about which Defendants failed to warn.

13 102. The Abilify manufactured and/or supplied to Plaintiff by Defendants was  
14 defective, dangerous, and had inadequate warnings or instructions at the time it was  
15 sold, and Defendants also acquired additional knowledge and information confirming  
16 the defective and dangerous nature of Abilify. Despite this knowledge and information,  
17 Defendants failed and neglected to issue adequate warnings or post-sale warnings that  
18 Abilify causes serious compulsive behaviors and harm.

19 103. Defendants failed to provide adequate warnings to users, purchasers, or  
20 prescribers of Abilify, including Plaintiff and Plaintiff's physicians, and instead  
21 continued to sell Abilify in an unreasonably dangerous form without adequate warnings  
22 or instructions.

23 104. By failing to adequately test and research compulsive behaviors and harms  
24 associated with Abilify use, and by failing to provide appropriate warnings about  
25 Abilify use and associations with compulsive behaviors such as gambling, patients and  
26 the medical community, including prescribing doctors, were inadequately informed  
27 about the true risk-benefit profile of Abilify and were not sufficiently aware that  
28 compulsive behaviors such as gambling might be associated with Abilify use. As such,

1 the medical community was not learned on the true risk-benefit profile of Abilify. Nor  
2 was the medical community, patients, patients' families, or regulators appropriately  
3 informed that compulsive behaviors such as gambling might be a side effect of Abilify  
4 use and should or could be reported as an adverse event.

5 105. As a direct and proximate result of Defendants' conduct, including the  
6 inadequate warnings, dilution or lack of information, lack of adequate testing and  
7 research, and the defective and dangerous nature of Abilify, Plaintiff has suffered, and  
8 will continue to suffer, neuropsychiatric and physical injury, emotional distress, harm,  
9 and economic loss as alleged herein.

10 **SECOND CAUSE OF ACTION**  
11 **Breach of Express Warranty by Defendants**

12 106. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
13 fully set forth herein and further alleges as follows:

14 107. Defendants expressly warranted to physicians and consumers, including  
15 Plaintiff and/or Plaintiff's physicians, that Abilify was safe and/or well-tolerated.

16 108. Abilify does not conform to these express representations because it is not safe  
17 and/or well-tolerated because it causes compulsive behaviors such as pathological  
18 gambling addiction which in turn can lead to financial ruin, job loss, familial  
19 devastation, and suicide attempts.

20 109. Also, Abilify's limited and unproven effectiveness did not outweigh the risks  
21 posed by the drug.

22 110. As a direct and proximate result of the breach of Defendants' warranties,  
23 Plaintiff has suffered, and will continue to suffer, neuropsychiatric and physical injury,  
24 emotional distress, harm, and economic loss as alleged herein.

25 **THIRD CAUSE OF ACTION**  
26 **Breach of Implied Warranty**

27 111. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
28 fully set forth herein and further alleges as follows:

1 112. At the time Defendants marketed, sold, and distributed Abilify, Defendants  
2 knew of the use for which Abilify was intended and impliedly warranted Abilify to be of  
3 merchantable quality, safe and fit for such use.

4 113. Defendants knew, or had reason to know, that Plaintiff and Plaintiff's  
5 physicians would rely on the Defendants' judgment and skill in providing Abilify for its  
6 intended use.

7 114. Plaintiff and Plaintiff's physician reasonably relied upon the skill and  
8 judgment of Defendants as to whether Abilify was of merchantable quality, safe, and fit  
9 for its intended use.

10 115. Contrary to such implied warranty, Abilify was not of merchantable quality or  
11 safe or fit for its intended use, because the product was, and is, unreasonably dangerous,  
12 defective and unfit for the ordinary purposes for which Abilify was used.

13 116. Also, Abilify's limited and unproven effectiveness did not outweigh the risks  
14 posed by the drug.

15 117. As a direct and proximate result of the breach of implied warranty, Plaintiff  
16 has suffered, and will continue to suffer, neuropsychiatric and physical injury,  
17 emotional distress, harm, and economic loss as alleged herein.

18 **FOURTH CAUSE OF ACTION**  
19 **Negligence**

20 118. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
21 fully set forth herein and further alleges as follows:

22 119. At all times material herein, Defendants had a duty to exercise reasonable care  
23 and the duty of an expert in all aspects of the design, formulation, manufacture,  
24 compounding, testing, inspection, packaging, labeling, distribution, marketing,  
25 promotion, advertising, sale, warning, and post-sale warning, testing, and research to  
26 assure the safety of the product when used as intended or in a way that Defendants  
27 could reasonably have anticipated, and to assure that the consuming public, including  
28 the Plaintiff and Plaintiff's physicians, obtained accurate information and adequate

1 instructions for the safe use or non-use of Abilify.

2 120. Defendants had a duty to warn Plaintiff, Plaintiff's physicians, and the public  
3 in general of Abilify's dangers and serious side effects, including serious compulsive  
4 behaviors like pathological gambling addiction, since it was reasonably foreseeable that  
5 an injury could occur because of Abilify's use.

6 121. At all times material herein, Defendants failed to exercise reasonable care and  
7 the duty of an expert and knew, or in the exercise of reasonable care should have  
8 known, that Abilify was not properly manufactured, designed, compounded, tested,  
9 inspected, packaged, labeled, warned about, distributed, marketed, advertised,  
10 formulated, promoted, examined, maintained, sold, and/or prepared.

11 122. Also, Abilify's limited and unproven effectiveness did not outweigh the risks  
12 posed by the drug.

13 123. Each of the following acts and omissions herein alleged was negligently and  
14 carelessly performed by Defendants, resulting in a breach of the duties set forth above.  
15 These acts and omissions include, but are not restricted to:

- 16 a. Negligent and careless research and testing of Abilify;
- 17 b. Negligent and careless design or formulation of Abilify;
- 18 c. Negligent and careless failure to give adequate warnings that would  
19 attract the attention of Plaintiff, Plaintiff's physicians, and the public in  
20 general of the potentially dangerous, defective, unsafe, and deleterious  
21 propensity of Abilify and of the risks associated with its use;
- 22 d. Negligent and careless failure to provide instructions on ways to safely use  
23 Abilify to avoid injury;
- 24 e. Negligent and careless failure to explain the mechanism, mode, and types  
25 of adverse events associated with Abilify;
- 26 f. Negligent representations that Abilify was safe and/or well-tolerated; and
- 27 g. Negligent and careless failure to issue adequate post-sale warnings that  
28 Abilify causes an increased risk of compulsive behaviors, including

1 pathological gambling.

2 124. As a direct and proximate result of Defendants' negligence, Plaintiff has  
3 suffered, and will continue to suffer, neuropsychiatric and physical injury, emotional  
4 distress, harm, and economic loss as alleged herein.

5 **FIFTH CAUSE OF ACTION**

6 Negligence Per Se

(Violations of 21 U.S.C. §§ 331, 352 and 21 C.F.R. §§ 201.56, 201.57, 202.1)

7 125. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
8 fully set forth herein and further alleges as follows:

9 126. At all times herein mentioned, Defendants had an obligation to abide by the  
10 law, including the Federal Food, Drug and Cosmetic Act and the applicable regulations,  
11 in the manufacture, design, formulation, compounding, testing, production, processing,  
12 assembling, inspection, research, promotion, advertising, distribution, marketing,  
13 labeling, packaging, preparation for use, consulting, sale, warning, and post-sale  
14 warning and other communications of the risks and dangers of Abilify.

15 127. By reason of its conduct as alleged herein, Defendants violated provisions of  
16 statutes and regulations, including, but not limited to, the following:

- 17 a. Defendants violated the Federal Food, Drug and Cosmetic Act, 21 U.S.C.  
18 §§ 331 and 352, by misbranding Abilify;
- 19 b. Defendants failed to follow the "[g]eneral requirements on content and  
20 format of labeling for human prescription drugs" in violation of 21 C.F.R. §  
21 201.56;
- 22 c. Defendants failed to follow the "[s]pecific requirements on content and  
23 format of labeling for human prescription drugs" in violation of 21 C.F.R. §  
24 201.57;
- 25 d. Defendants advertised and promoted Abilify in violation of 21 C.F.R. §  
26 202.1; and
- 27 e. Defendants violated 21 C.F.R. § 201.57(e) by failing to timely and  
28 adequately change the Abilify label to reflect the evidence of an association

1 between Abilify and the serious compulsive behaviors suffered by  
2 Plaintiff.

3 128. These statutes and regulations impose a standard of conduct designed to  
4 protect consumers of drugs, including Plaintiff.

5 129. Defendants' violations of these statutes and regulations constitute negligence  
6 per se.

7 130. As a direct and proximate result of Defendants' statutory and regulatory  
8 violations, Plaintiff, a member of the class of persons protected by the above-mentioned  
9 statutes, has suffered, and will continue to suffer, neuropsychiatric and physical injury,  
10 emotional distress, harm, and economic loss as alleged herein.

11 **SIXTH CAUSE OF ACTION**  
12 **Negligent Misrepresentation**

13 131. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
14 fully set forth herein and further alleges as follows:

15 132. Defendants misrepresented to consumers and physicians, including Plaintiff  
16 and/or Plaintiff's physicians and the public in general, that Abilify was safe and/or  
17 well-tolerated when used as instructed, and that Abilify showed that Abilify was safe  
18 and/or well-tolerated, when, in fact, Abilify was dangerous to the well-being of patients.

19 133. Also, Abilify's limited and unproven effectiveness did not outweigh the risks  
20 posed by the drug.

21 134. At the time Defendants promoted Abilify as safe and/or well-tolerated, they  
22 did not have adequate proof upon which to base such representations, and, in fact, knew  
23 or should have known that Abilify was dangerous to the well-being of Plaintiff and  
24 others.

25 135. Defendants failed to exercise reasonable care and competence in obtaining  
26 and/or communicating information regarding the safe use of Abilify and otherwise  
27 failed to exercise reasonable care in transmitting information to Plaintiff, Plaintiff's  
28 physicians, and the public in general.



1 136. Defendants made the aforesaid representations in the course of defendants'  
2 business as designers, manufacturers, and distributors of Abilify despite having no  
3 reasonable basis for their assertion that these representations were true and/or without  
4 having accurate or sufficient information concerning the aforesaid representations.  
5 Defendants were aware that without such information they could not accurately make  
6 the aforesaid representations.

7 137. At the time the aforesaid representations were made, Defendants intended to  
8 induce Plaintiff and/or Plaintiff's physicians to rely upon such representations.

9 138. At the time the aforesaid representations were made by Defendants, and at the  
10 time Plaintiff received Abilify, Plaintiff and/or Plaintiff's physicians, and the public in  
11 general reasonably believed them to be true. In reasonable and justified reliance upon  
12 said representations by Plaintiff and/or Plaintiff's physicians, Plaintiff used Abilify.

13 139. As a direct and proximate result of reliance upon Defendants'  
14 misrepresentations, Plaintiff has suffered, and will continue to suffer, neuropsychiatric  
15 and physical injury, emotional distress, harm, and economic loss as alleged herein.

16 **SEVENTH CAUSE OF ACTION**  
17 **Violation of Violation of California Unfair Competition Law**  
18 **and Consumers Legal Remedies Act**

19 140. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
20 fully set forth herein and further alleges as follows:

21 141. By reason of the conduct as alleged herein, and by inducing Plaintiff and  
22 Plaintiff's physicians to use Abilify through the use of deception, fraud, false  
23 advertising, false pretenses, misrepresentations, unfair and/or deceptive practices and  
24 the concealment and suppression of material facts, including but not limited to  
25 fraudulent statements, concealments and misrepresentations identified herein and  
26 above, Defendants violated the provisions of Cal. Bus. & Prof. Code §17200 *et seq.* and  
27 Cal. Civ. Code §1750 *et seq.*

28 142. As a direct and proximate result of Defendants' statutory violations, Plaintiff  
was damaged by Abilify which would not have occurred had Defendants not used

1 deception, fraud, false advertising, false pretenses, misrepresentations, unfair and/or  
2 deceptive practices and the concealment and suppression of material facts to induce  
3 Plaintiff and Plaintiff's physicians to use this products.

4 143. By reason of such violations and pursuant to Cal. Bus. & Prof. Code §17200 *et*  
5 *seq.* and Cal. Civ. Code §1750 *et seq.*, Plaintiff is entitled to recover all of the monies paid  
6 for Abilify; to be compensated for the cost of the medical care arising out of the use of  
7 Abilify; and to recover any and all consequential damages recoverable under the law  
8 including, but not limited to, gambling losses, both past and future medical expenses,  
9 past wage loss, loss of future earning capacity, past and future pain, suffering, disability,  
10 and emotional distress. Plaintiff is entitled to seek compensatory damages, attorney's  
11 fees, and other remedies as determined by the Court pursuant to Cal. Bus. & Prof. Code  
12 §17200 *et seq.* and Cal. Civ. Code §1750 *et seq.*

13 **EIGHTH CAUSE OF ACTION**  
14 **Fraudulent Concealment**

15 144. Plaintiff incorporates the factual allegations set forth in paragraphs 1 to 94 as if  
16 fully set forth herein and further alleges as follows:

17 145. Throughout the relevant time period, Defendants knew that Abilify was  
18 defective and unreasonably unsafe for its intended purpose.

19 146. Defendants fraudulently concealed from or failed to disclose to or warn  
20 Plaintiff, physicians, and the medical community that Abilify was defective, unsafe,  
21 unfit for the purposes intended, and was not of merchantable quality.

22 147. Defendants were under a duty to Plaintiff to disclose and warn of the  
23 defective nature of Abilify because:

- 24 a. Defendants were in a superior position to know the true quality, safety and  
25 efficacy of Abilify;
- 26 b. Defendants knowingly made false claims about the safety and quality of  
27 Abilify in the documents and marketing materials Defendants provided to  
28 the FDA, physicians, and the general public; and

1 c. Defendants fraudulently and affirmatively concealed the defective nature  
2 of Abilify from Plaintiff.

3 148. Defendants were under a duty to Plaintiff to disclose and warn of the  
4 defective nature of Abilify because the facts concealed or not disclosed by Defendants to  
5 Plaintiff were material facts that a reasonable person would have considered to be  
6 important in deciding whether or not to purchase or use the product.

7 149. Defendants intentionally concealed or failed to disclose the true defective  
8 nature of Abilify so that Plaintiff would request and purchase the Abilify, and that their  
9 healthcare providers would dispense, prescribe, and recommend Abilify, and Plaintiff  
10 justifiably acted or relied upon, to Plaintiff's detriment, the concealed or non-disclosed  
11 facts as evidenced by their purchase and use of Abilify.

12 150. Defendants, by concealment or other action, intentionally prevented Plaintiff  
13 and Plaintiff's physicians from acquiring material information regarding the lack of  
14 safety and effectiveness of Abilify, and are subject to the same liability to Plaintiff for  
15 Plaintiff's pecuniary losses, as though Defendants had stated the non-existence of such  
16 material information regarding Abilify's lack of safety and effectiveness and dangers  
17 and defects, and as though Defendants had affirmatively stated the non-existence of  
18 such matters that Plaintiff was thus prevented from discovering the truth. Defendants  
19 therefore have liability for fraudulent concealment under all applicable law, including,  
20 *inter alia*, Restatement (Second) of Torts § 550 (1977).

21 151. As a result of Defendants' foregoing acts and omissions, Plaintiffs were or still  
22 are caused to suffer or are a greatly increased risk of serious and dangerous side effects  
23 including compulsive gambling, and other severe and personal injuries, physical pain  
24 and mental anguish, diminished enjoyment of life, any and all life complications.

25 152. As a direct and proximate result of the foregoing acts and omissions, Plaintiff  
26 has required and will require healthcare and services, and has incurred financial loss,  
27 medical, health care, incidental, and related expenses.

28 153. As a direct and proximate result of reliance upon Defendants'

1 misrepresentations, Plaintiff has suffered, and will continue to suffer, neuropsychiatric  
2 and physical injury, emotional distress, harm, and economic loss as alleged herein.

3  
4 **NINTH CAUSE OF ACTION**  
**Punitive Damages**

5 154. Plaintiffs incorporates the factual allegations set forth in paragraphs 1 to 94 as  
6 if fully set forth herein and further alleges as follows:

7 155. Plaintiffs are entitled to an award of punitive and exemplary damages based  
8 upon Defendants' intentional, willful, knowing, fraudulent, malicious acts, omissions,  
9 and conduct, and Defendants' reckless disregard for the public safety and welfare.  
10 Defendants intentionally and fraudulently misrepresented facts and information to both  
11 the medical community and the general public, including Plaintiff, by making  
12 intentionally false and fraudulent misrepresentations about the safety and efficacy of  
13 Abilify. Defendants intentionally concealed the true facts and information regarding the  
14 serious risks of harm associated with the ingestion of Abilify, and intentionally  
15 downplayed the type, nature, and extent of the adverse side effects of ingesting Abilify,  
16 despite Defendants' knowledge and awareness of the serious side effects and risks  
17 associated with Abilify.

18 156. Defendants had knowledge of, and were in possession of evidence  
19 demonstrating that Abilify caused serious side effects including compulsive gambling.  
20 Notwithstanding Defendants' knowledge of the serious side effects of Abilify,  
21 Defendants continued to market the drug by providing false and misleading  
22 information with regard to the product's safety and efficacy to the regulatory agencies,  
23 the medical community, and consumers of Abilify.

24 157. Although Defendants knew or recklessly disregarded the fact that Abilify  
25 cause debilitating compulsive behavior side effects including compulsive gambling,  
26 Defendants continued to market, promote, and distribute Abilify to consumers,  
27 including Plaintiff, without disclosing these side effects when there were safer  
28 alternative methods for treating Plaintiff's underlying condition.

1 158. Defendants failed to provide warnings that would have dissuaded physicians  
2 from prescribing Abilify and consumers from purchasing and ingesting Abilify, thus  
3 depriving both from weighing the true risks against the benefits of prescribing,  
4 purchasing or consuming the Abilify.

5 159. Defendants knew of Abilify's defective nature as set forth herein, but  
6 continued to design, manufacture, market, distribute, sell and/or promote the drug as to  
7 maximize sales and profits at the expense of the health and safety of the public,  
8 including Plaintiffs in a conscious or negligent disregard of the foreseeable harm caused  
9 by Abilify.

10 160. The aforementioned conduct of Defendants was committed with knowing,  
11 conscious, and deliberate disregard of the rights and safety of consumers such as  
12 Plaintiff, thereby entitling Plaintiff to punitive damages in the amount appropriate to  
13 punish Defendants and deter them from similar conduct in the future.

14 **PRAYER FOR RELIEF**

15 WHEREFORE, Plaintiff seeks judgment in Plaintiff's favor as follows:

- 16 1. Awarding actual damages to Plaintiff incidental to the purchase and  
17 ingestion of Abilify in an amount to be determined at trial;
- 18 2. Awarding the costs of treatment for Plaintiff's injuries caused by  
19 Abilify;
- 20 3. Awarding damages for Plaintiff's neuropsychiatric, mental,  
21 physical, and economic pain and suffering;
- 22 4. Awarding damages for Plaintiff's mental and emotional anguish;
- 23 5. Awarding pre-judgment and post-judgment interest to Plaintiff;
- 24 6. Awarding punitive damages;
- 25 7. Awarding the costs and expenses of this litigation to Plaintiff;
- 26 8. Awarding reasonable attorneys' fees and costs to Plaintiff as  
27 provided by law;
- 28



CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS Athalean Harper-Mosley (b) County of Residence of First Listed Plaintiff Sacramento (c) Attorneys (Firm Name, Address, and Telephone Number) Gary Wilson, Robins Kaplan LLP, 800 LaSalle Avenue, Suite 2800, Minneapolis, MN 55402. DEFENDANTS Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., and Otsuka America Pharmaceutical, Inc. County of Residence of First Listed Defendant New York. Attorneys (If Known) Barry Thompson, Esq., Hogan Lovells US LLP, 1999 Avenue of the Stars, Suite 1400, Los Angeles, CA 90067; Matthew Campbell, Esq., Winston & Strawn LLP, 1700 K Street, NW, Washington, D.C. 20006-3817.

II. BASIS OF JURISDICTION (Place an "X" in One Box Only) 1 U.S. Government Plaintiff, 2 U.S. Government Defendant, 3 Federal Question (U.S. Government Not a Party), 4 Diversity (Indicate Citizenship of Parties in Item III). III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant) Citizen of This State, Citizen of Another State, Citizen or Subject of a Foreign Country, PTF DEF, Incorporated or Principal Place of Business In This State, Incorporated and Principal Place of Business In Another State, Foreign Nation.

IV. NATURE OF SUIT (Place an "X" in One Box Only) CONTRACT, REAL PROPERTY, TORTS, CIVIL RIGHTS, PRISONER PETITIONS, FORFEITURE/PENALTY, LABOR, IMMIGRATION, BANKRUPTCY, SOCIAL SECURITY, FEDERAL TAX SUITS, OTHER STATUTES.

V. ORIGIN (Place an "X" in One Box Only) 1 Original Proceeding, 2 Removed from State Court, 3 Remanded from Appellate Court, 4 Reinstated or Reopened, 5 Transferred from Another District (specify), 6 Multidistrict Litigation.

VI. CAUSE OF ACTION Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity): 28 U.S.C. § 1332. Brief description of cause: Products liability action regarding prescription drug Abilify.

VII. REQUESTED IN COMPLAINT: CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. DEMAND \$ over \$75,000. CHECK YES only if demanded in complaint: JURY DEMAND: Yes No.

VIII. RELATED CASE(S) IF ANY (See instructions): JUDGE See attachment; Lawrence J. O'Neill DOCKET NUMBER 1:16-cv-00065-LJO-BAM

DATE 04/20/2016 SIGNATURE OF ATTORNEY OF RECORD /s/ Gary L. Wilson

FOR OFFICE USE ONLY RECEIPT # AMOUNT APPLYING IFP JUDGE MAG. JUDGE



Case 2:16-cv-00817-JAM-EFB Document 1-1 Filed 04/20/16 Page 2 of 5  
**INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44**

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I. (a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence.** For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys.** Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- II. Jurisdiction.** The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.  
 United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here.  
 United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.  
 Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.  
 Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)
- III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- IV. Nature of Suit.** Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerk(s) in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.
- V. Origin.** Place an "X" in one of the six boxes.  
 Original Proceedings. (1) Cases which originate in the United States district courts.  
 Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.  
 Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.  
 Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.  
 Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.  
 Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.
- VI. Cause of Action.** Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service
- VII. Requested in Complaint.** Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.  
 Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction.  
 Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases.** This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

**Date and Attorney Signature.** Date and sign the civil cover sheet.

**ATTACHMENT FOR CIVIL COVER SHEET**

Attorneys for Plaintiff(s):

Gary L. Wilson  
Munir R. Meghjee  
Megan L. McKenzie  
Robins Kaplan LLP  
800 LaSalle Avenue  
Suite 2800  
Minneapolis, MN 55402-2015  
Telephone: (612) 349-8500

**Related Cases**

No.	Case	Case Docket	Judge	Date Terminated
1	Daniel Thomas v. Bristol-Myers Squibb Company, et al.	2:16-cv-00326-PA-AGR (C.D. Cal.)	District Judge Percy Anderson and Magistrate Judge Alicia G. Rosenberg	n/a
2	Stephanie Pamintuan v. Bristol-Myers Squibb Company, et al.	4:16-cv-00254-DMR (N.D. Cal.)	District Judge Haywood S Gilliam, Jr. and Magistrate Judge Donna M. Ryu	n/a
3	Brenda Sears v. Bristol-Myers Squibb Company, et al.	1:16-cv-00065-LJO-BAM (E.D. Cal)	District Judge Lawrence J. O'Neill and Magistrate Barbara A. McAuliffe	n/a
4	Karen Reynolds v. Bristol-Myers Squibb Company, et al.	1:16-cv-00357-LJO-BAM (E.D. Cal)	District Judge Lawrence J. O'Neill and Magistrate Barbara A. McAuliffe	n/a
5	Denise Miley v. Bristol-Myers Squibb Company, et al.	0:16-cv-00067-MJD-JSM (D. Minn.)	Judge Patrick J. Schiltz and Magistrate Judge Janie S. Mayeron	n/a
6	Sean Brazil v. Bristol-Myers Squibb Company, et al.	1:16-cv-00271 (S.D.N.Y.)	Judge Naomi Reice Buchwald and Magistrate Judge Sarah Netburn	n/a

No.	Case	Case Docket	Judge	Date Terminated
7	Marc Tripler v. Bristol-Myers Squibb Company, et al.	2:16-cv-00244-PBT (E.D. Pa.)	Chief Judge Petrese Tucker	n/a
8	Ben Bowman v. Bristol-Myers Squibb Company, et al.	8:16-cv-00117-JDW-JSS (M.D. Fla.)	District Judge James D. Whittemore and Magistrate Judge Julie S. Sneed	n/a
9	Wilette Reese v. Bristol-Myers Squibb Company, et al.	8:16-cv-00116-SDM-MAP (M.D. Fla.)	District Judge Steven D. Merryday and Magistrate Judge Mark A. Pizzo	n/a
10	Nicholas Meyer v. Bristol-Myers Squibb Company, et al.	1:16-cv-00191-SEB-MJD (S.D. Ind.)	District Judge Sarah Evans Barker and Magistrate Mark J. Dinsmore	n/a
11	Thomas LeLand v. Bristol-Myers Squibb Company, et al.	16-cv-03023-S-MDH (W.D. Mo)	District Judge M. Douglas Harpool	n/a
12	Stephan Butler v. Bristol-Myers Squibb Company, et al.	1:16-cv-00173-ELH (D. Md.)	District Judge Ellen L. Hollander	n/a
13	James Davis v. Bristol-Myers Squibb Company, et al.	1:16-cv-00171-ELH (D. Md.)	District Judge Ellen L. Hollander	n/a
14	Diana Kinder v. Bristol-Myers Squibb Company, et al.	1:16-cv-00170-ELH (D. Md.)	District Judge Ellen L. Hollander	n/a
15	Matthew Schaap v. Bristol-Myers Squibb Company, et al.	1:16-cv-00172-ELH (D. Md.)	District Judge Ellen L. Hollander	n/a
16	Angel Clark v. Bristol-Myers Squibb Company, et al.	3:16-cv-01313-MAS-TJB (D. N.J.)	District Judge Michael A. Shipp and Magistrate Judge Tonianne J. Bongiovanni	n/a
17.	*Debra Cottrell v. Bristol-Myers Squibb Company, et al.	3:16-cv-01802-MAS-TJB (D. N.J.)	District Judge Michael A. Shipp and Magistrate Judge Tonianne J. Bongiovanni	n/a
18.	*Geneva Johnson v. Bristol-Myers Squibb Company, et al.	3:16-cv-01841-MAS-TJB (D. N.J.)	District Judge Michael A. Shipp and Magistrate Judge Tonianne J. Bongiovanni	n/a

- \* Plaintiff will be filing a Motion to Remand to Superior Court of New Jersey Law Division, Bergen County shortly.